In patients with high-risk HER2-positive breast cancer, post-surgery, or adjuvant, treatment with trastuzumab emtansine ...

Patients with HER-2 positive early breast cancer with residual invasive disease after neoadjuvant therapy were randomly ...

Adjuvant ado-trastuzumab emtansine significantly prolonged survival compared with trastuzumab for certain women with ...

The therapy, dubbed OST-HER2, uses a HER2-bioengineered form of the bacteria Listeria monocytogenes to trigger an immune ...

Incredible” results from the PATINA trial suggested a new standard of care for HER2, ER-positive metastatic breast cancer.

REVEAL GENOMICS, S.L., a Barcelona-based biotechnology start-up seeking to revolutionize precision oncology through biomarker ...